Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: Diagnostic and biologic implications
Timothy P. Seybt, Preetha Ramalingam, Jie Huang, Stephen Warwick Looney, Michelle D. Reid
Biostats & Data Science
Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52% vs. 88% respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88% vs. 61%, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52% vs. 89%, respectively; P=0.003) and PTCFV (52% vs. 88%, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61% vs. 89%, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.
Applied Immunohistochemistry and Molecular Morphology
https://doi.org/10.1097/PAI.0b013e31822d4783
Factor IX
Papillary Thyroid cancer
thyroid carcinoma
thyroid tumors
Medical Laboratory Technology
Seybt, T. P., Ramalingam, P., Huang, J., Looney, S. W., & Reid, M. D. (2012). Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: Diagnostic and biologic implications. Applied Immunohistochemistry and Molecular Morphology, 20(2), 124-130. https://doi.org/10.1097/PAI.0b013e31822d4783
Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland : Diagnostic and biologic implications. / Seybt, Timothy P.; Ramalingam, Preetha; Huang, Jie; Looney, Stephen Warwick; Reid, Michelle D.
In: Applied Immunohistochemistry and Molecular Morphology, Vol. 20, No. 2, 01.03.2012, p. 124-130.
Seybt, TP, Ramalingam, P, Huang, J, Looney, SW & Reid, MD 2012, 'Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: Diagnostic and biologic implications', Applied Immunohistochemistry and Molecular Morphology, vol. 20, no. 2, pp. 124-130. https://doi.org/10.1097/PAI.0b013e31822d4783
Seybt TP, Ramalingam P, Huang J, Looney SW, Reid MD. Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: Diagnostic and biologic implications. Applied Immunohistochemistry and Molecular Morphology. 2012 Mar 1;20(2):124-130. https://doi.org/10.1097/PAI.0b013e31822d4783
Seybt, Timothy P. ; Ramalingam, Preetha ; Huang, Jie ; Looney, Stephen Warwick ; Reid, Michelle D. / Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland : Diagnostic and biologic implications. In: Applied Immunohistochemistry and Molecular Morphology. 2012 ; Vol. 20, No. 2. pp. 124-130.
@article{f369f1b1df314eb78325331b6dfe2f19,
title = "Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland: Diagnostic and biologic implications",
abstract = "Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52{\%} vs. 88{\%} respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88{\%} vs. 61{\%}, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52{\%} vs. 89{\%}, respectively; P=0.003) and PTCFV (52{\%} vs. 88{\%}, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61{\%} vs. 89{\%}, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.",
keywords = "cyclin D1, thyroid carcinoma, thyroid tumors",
author = "Seybt, {Timothy P.} and Preetha Ramalingam and Jie Huang and Looney, {Stephen Warwick} and Reid, {Michelle D.}",
doi = "10.1097/PAI.0b013e31822d4783",
journal = "Applied Immunohistochemistry and Molecular Morphology",
T1 - Cyclin D1 expression in benign and differentiated malignant tumors of the thyroid gland
T2 - Diagnostic and biologic implications
AU - Seybt, Timothy P.
AU - Ramalingam, Preetha
AU - Huang, Jie
AU - Looney, Stephen Warwick
AU - Reid, Michelle D.
N2 - Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52% vs. 88% respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88% vs. 61%, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52% vs. 89%, respectively; P=0.003) and PTCFV (52% vs. 88%, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61% vs. 89%, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.
AB - Cyclin D1 expression was examined in benign and differentiated malignant thyroid tumors to determine diagnostic utility and correlation with tumor type, size, and nodal status; 29 follicular adenomas (FA), 23 follicular carcinomas (FCA) and 43 papillary thyroid carcinomas (PTC) (22 with and 21 without nodal metastases) were stained. PTCs included 27 classical (PTCC) and 16 follicular variants (PTCFV). A statistically significant association was found between tumor type and cyclin D1 staining, distribution, and intensity. There were fewer cyclin D1-positive FAs than PTCs (52% vs. 88% respectively; P<0.001) and stain distribution was greater in PTC than FA (P=0.032). More PTCs were positive than FCAs (88% vs. 61%, respectively; P=0.013). All significant comparisons remained significant after adjusting for tumor size. FA did not differ from FCA in staining/intensity. There were fewer cyclin D1-positive FAs than PTCC (52% vs. 89%, respectively; P=0.003) and PTCFV (52% vs. 88%, respectively; P=0.023). FCA also differed significantly from PTCC in staining (61% vs. 89%, respectively; P=0.044) and intensity (P=0.024). In terms of cyclin D1 intensity, FA had significantly less intense staining than PTCC (P=0.004). No significant associations were found between PTC nodal status and any cyclin D1 characteristic. In conclusion, cyclin D1 shows heterogeneity in distribution and intensity in benign and malignant thyroid tumors, which disqualifies it as a primary diagnostic marker in these tumors; however, it may be helpful in distinguishing FA from PTC, especially PTCFV. Its expression by thyroid tumors suggests a role in tumor development and may be an early event in thyroid neoplasia.
KW - cyclin D1
KW - thyroid carcinoma
KW - thyroid tumors
U2 - 10.1097/PAI.0b013e31822d4783
DO - 10.1097/PAI.0b013e31822d4783
JO - Applied Immunohistochemistry and Molecular Morphology
JF - Applied Immunohistochemistry and Molecular Morphology
10.1097/PAI.0b013e31822d4783